Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Basilea Pharmaceutica AG
  6. News
  7. Summary
    BSLN   CH0011432447

BASILEA PHARMACEUTICA AG

(BSLN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Basilea Pharmaceutica Ag Reports Earnings Results for the Half Year Ended June 30, 2021

08/17/2021 | 05:59am EDT

Basilea Pharmaceutica AG announced earnings results for the half year ended June 30, 2021. For the half year, the company announced total revenue was CHF 54.198 million compared to CHF 69.328 million a year ago. Operating loss was CHF 15.355 million compared to operating Income of CHF 12.814 million a year ago. Net loss was CHF 19.891 million compared to net income of CHF 9.941 million a year ago. Basic loss per share from continuing operations was CHF 1.84 compared to basic earnings per share from continuing operations of CHF 0.92 a year ago. Diluted loss per share from continuing operations was CHF 1.84 compared to diluted earnings per share from continuing operations of CHF 0.91 a year ago.


© S&P Capital IQ 2021
All news about BASILEA PHARMACEUTICA AG
10/11BASILEA PHARMACEUTICA : Therapy Shows Synergistic Anti-Tumor Effects In Gastric Cancer Mod..
MT
10/11PRESS RELEASE : Basilea presents preclinical data -2-
DJ
10/11Basilea presents preclinical data on synergy between derazantinib and paclitaxel in gas..
DJ
10/11PRESS RELEASE : Basilea presents preclinical data on synergy between derazantinib and pacl..
DJ
10/11Basilea Pharmaceutica Ltd Presents Preclinical Data on Synergy Between Derazantinib and..
CI
09/30BASILEA PHARMACEUTICA : Asahi Kasei Seek Japanese Nod For Anti-Fungal Drug
MT
09/30Basilea's partner Asahi Kasei Pharma filed New Drug Application for the marketing autho..
DJ
09/30PRESS RELEASE : Basilea's partner Asahi Kasei Pharma filed New Drug Application for the ma..
DJ
09/30BASILEA PHARMACEUTICA : partner Asahi Kasei Pharma filed New Drug Application for the mark..
AQ
09/17BASILEA PHARMACEUTICA : Bile Duct Cancer Drug Shows Improved Efficacy In Updated Mid-Stage..
MT
More news
Analyst Recommendations on BASILEA PHARMACEUTICA AG
More recommendations
Financials
Sales 2021 138 M 150 M 150 M
Net income 2021 -22,2 M -24,3 M -24,3 M
Net cash 2021 0,85 M 0,93 M 0,93 M
P/E ratio 2021 -21,6x
Yield 2021 -
Capitalization 506 M 552 M 552 M
EV / Sales 2021 3,67x
EV / Sales 2022 3,00x
Nbr of Employees 160
Free-Float 88,5%
Chart BASILEA PHARMACEUTICA AG
Duration : Period :
Basilea Pharmaceutica AG Technical Analysis Chart | BSLN | CH0011432447 | MarketScreener
Technical analysis trends BASILEA PHARMACEUTICA AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 42,86 CHF
Average target price 87,60 CHF
Spread / Average Target 104%
EPS Revisions
Managers and Directors
David Veitch Chief Executive Officer
Adesh Kaul Chief Financial Officer
Domenico Scala Chairman
Laurenz Kellenberger Chief Scientific Officer
Marc Engelhardt Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
BASILEA PHARMACEUTICA AG-19.36%552
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 092
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-38.86%25 455